The Advanced Therapies model of Lund an integrated approach to accelerate access for many patients

MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · Published 2025-11-25 · DOI 10.1016/j.omtm.2025.101637

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.omtm.2025.101637

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Systemic mRNA-LNP administration in fetuses improves survival in a mouse model of spinal muscular atrophy · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
Protocol of generation of tolerogenic dendritic cells affects their transcriptional and metabolic profiles leading to specific tolerogenic functions · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
SLC20A1 knockout to stably express a fusogenic gibbon ape leukemia virus envelope glycoprotein for lentiviral vector production · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
Bilateral retinal rescue through unilateral AAV8-CYP4V2 gene delivery in Bietti crystalline dystrophy · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
Toward CAR-B cells for HIV-1 therapy · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
Gene therapy supports long-term reconstitution of patient hematopoietic stem cells in deficiency of adenosine deaminase 2 · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
Modified AAV5 capsid for improved brain biodistribution following direct injection in preclinical models · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
Design of cationic ionizable lipids for the delivery of therapeutic nucleic acids · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal
Should patients with pre-existing anti-AAV antibodies be excluded from receiving intrathecally delivered AAV vectors? · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Same journal